Portfolio Update : Correction
The Board of OT4 VCT notes that Arecor Therapeutics plc (Arecor), which at 31 May 2021 was 53 % of the OT4 NAV of 30.8p/share was based on an Arecor share price of £2.26 which has now risen to £4.30 bid price as at market close on 23 September. In isolation, each 100p change in Arecor's share price has a 7.15p impact on the NAV of OT4 VCT.
The Board are in the process of preparing the accounts for the half year ending 31 August 2021, which will including further details of the valuation of the rest of the portfolio. These are expected to be issued in October.
For further information please contact: Lucius Cary 01865 784466
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a Regulatory Information Service, this information is now considered to be in the public domain.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Landsbankinn hf.: Financial results for Q1 2024 to be published 2 May 2024
- Tquila announces launch and first close of $60 million Tquila Paloma Fund, marking milestone in tech venture investment
- FFW Corporation Announces Earnings for the Quarter and Year to Date Ended March 31, 2024
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!